Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Louvet, C.
Right arrow Articles by Krulik, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Louvet, C.
Right arrow Articles by Krulik, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 2:229-230, 1991
© 1991 European Society for Medical Oncology

brief-report

Short report: High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer

C. Louvet, A. de Gramont, B. Demuynck, B. Nordlinger, J.-E. Maisani, B. Lagadec, S. Delfau, C. Varette, G. Gonzalez-Canali and M. Krulik

GERCOD (Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs), Hôspital Saint-Antoine Paris, France

Correspondence to: Christophe Louvet, M.D., Service du Pr Krulik, Hôspital St-Antoine, 184 rue du Fbg St-Antoine, 75012, Paris, France

Twenty-five patients with advanced measurable gastric cancer were treated with high-dose folinic acid (200 mg/m2), 5-fluorouracil bolus (400 mg/m2) and continuous infusion (600 mg/m2) for two consecutive days every two weeks. Fourteen patients over 65 yr old and/or with a poor general status received first-line treatment, and eleven younger patients second-line. The response rate was 43.5% in 23 evaluable patients. There were 2 complete responses (8.7%) and 8 partial responses (34.8%). Median survival was 6 months in first-line and 8 months, calculated from start of folinic acid-5FU, in second-line. Toxicity was mild without WHO Grade >2 events. This combination is effective for advanced gastric cancer in poor-prognosis patients and requires further studies.

chemotherapy, Gastric cancer, 5-fluorouracil, folinic acid


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Kawakami, F. Graziano, G. Watanabe, A. Ruzzo, D. Santini, V. Catalano, R. Bisonni, F. Arduini, I. Bearzi, S. Cascinu, et al.
Prognostic Role of Thymidylate Synthase Polymorphisms in Gastric Cancer Patients Treated with Surgery and Adjuvant Chemotherapy
Clin. Cancer Res., May 15, 2005; 11(10): 3778 - 3783.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Bouche, J. L. Raoul, F. Bonnetain, M. Giovannini, P. L. Etienne, G. Lledo, D. Arsene, J. F. Paitel, V. Guerin-Meyer, E. Mitry, et al.
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803
J. Clin. Oncol., November 1, 2004; 22(21): 4319 - 4328.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Mitry, J. Taieb, P. Artru, V. Boige, J.-N. Vaillant, M.-C. Clavero-Fabri, M. Ducreux, and P. Rougier
Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma
Ann. Onc., May 1, 2004; 15(5): 765 - 769.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Louvet, T. Andre, J.M. Tigaud, E. Gamelin, J.Y. Douillard, R. Brunet, E. Francois, J.H. Jacob, D. Levoir, A. Taamma, et al.
Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients
J. Clin. Oncol., December 1, 2002; 20(23): 4543 - 4548.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. C. Tebbutt, A. Norman, D. Cunningham, T. Iveson, M. Seymour, T. Hickish, P. Harper, N. Maisey, K. Mochlinski, Y. Prior, et al.
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
Ann. Onc., October 1, 2002; 13(10): 1568 - 1575.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.